Biological statistics professionals must master precise terminology for p-values, confidence intervals, and regulatory submissions where small errors invalidate entire studies. Clear communication of complex statistical concepts to non-statistician stakeholders is equally critical for successful clinical programs.

Our biostatistics editorial assessment features real regulatory scenarios with CDISC terminology, power calculations, and interim analyses. This targeted evaluation identifies candidates who can accurately edit statistical analysis plans and clinical study reports under strict regulatory requirements.

Illustrative scenario

Biostatistics Report Error Triggers FDA Complete Response Letter

A biostatistician incorrectly described multiplicity adjustments in a pivotal trial's statistical analysis plan, using 'Bonferroni correction' when 'Hochberg procedure' was actually implemented. The FDA issued a Complete Response Letter questioning the statistical validity, delaying the $2.3 billion drug approval by eight months.

A composite example of a failure mode that is common in Biological Statistics. It is not an account of a real client engagement and no real organisation is described.

Documents You'll Be Testing

Statistical Analysis Plan
Clinical Study Report
Interim Analysis Report
Biostatistics Review Memorandum
Protocol Amendment
DMC Charter

Avoid These Common Editorial Mistakes

Confusing statistical and clinical significance

Regulatory queries questioning study interpretation and conclusions

Incorrect confidence interval notation

FDA requests for clarification delaying submission review timelines

Misidentifying statistical test methodology

Regulatory rejection of statistical approach requiring costly protocol amendments

Wrong p-value adjustment terminology

Questions about multiplicity control affecting primary endpoint validity

Imprecise population definition language

Confusion about analysis sets affecting regulatory approval scope

Master These Key Terms

Significant vs Statistically significant
Superiority vs Non-inferiority
Intent-to-treat vs Per-protocol
Type I error vs Type II error
Interim analysis vs Final analysis

Smart Hiring Strategies

Prioritize candidates who demonstrate precision with statistical terminology and understand regulatory submission standards like CDISC and ICH guidelines. Test their ability to distinguish clinical from statistical significance and explain complex concepts clearly to diverse stakeholders.

Biological statistics documentation operates under strict regulatory oversight where terminology errors can delay drug approvals and affect patient safety decisions. Editorial precision directly impacts multi-million dollar development programs and regulatory compliance.

Frequently Asked Questions

How technical should our biostatistics candidates' writing skills be? ↓
Candidates need to write for multiple audiences - from FDA statisticians requiring precise technical terminology to clinical teams needing clear interpretations. Test their ability to explain p-values, confidence intervals, and study results without oversimplifying or losing regulatory precision.
What level of regulatory knowledge should we expect in writing samples? ↓
Look for understanding of ICH E9 statistical principles, FDA guidance documents, and submission requirements. Candidates should demonstrate familiarity with CDISC standards and regulatory terminology even if they're not regulatory specialists themselves.
Should we test knowledge of specific statistical software in writing assessments? ↓
Focus on statistical concept communication rather than software syntax. However, candidates should understand output interpretation and be able to describe analyses clearly regardless of whether they used SAS, R, or other platforms.
How important is medical writing experience versus pure statistics background? ↓
Both matter, but prioritise statistical accuracy over medical writing style. A biostatistician who misuses statistical terms poses greater regulatory risk than one with awkward prose but correct methodology descriptions.
What red flags should we watch for in biostatistics writing samples? ↓
Confusion between correlation and causation, misuse of 'significant' without 'statistically', incorrect confidence interval interpretations, and vague population definitions. These errors can compromise regulatory submissions and require expensive corrections.